Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Common Equity (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Common Equity for 5 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 28.87% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 28.87% year-over-year, with the annual reading at $1.2 billion for FY2025, 28.87% up from the prior year.
  • Common Equity hit $1.2 billion in Q4 2025 for Krystal Biotech, up from $1.1 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.2 billion in Q4 2025 to a low of $408.2 million in Q3 2021.
  • Historically, Common Equity has averaged $727.6 million across 5 years, with a median of $704.5 million in 2023.
  • Biggest five-year swings in Common Equity: fell 12.02% in 2022 and later surged 63.26% in 2024.
  • Year by year, Common Equity stood at $593.6 million in 2021, then dropped by 12.02% to $522.2 million in 2022, then soared by 49.1% to $778.6 million in 2023, then rose by 21.54% to $946.4 million in 2024, then rose by 28.87% to $1.2 billion in 2025.
  • Business Quant data shows Common Equity for KRYS at $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.0 billion in Q2 2025.